Molecular Phenotypes for Lung Diseases
Molecular Phenotypes for Lung Diseases
批准号:
8112589
负责人:
DAVID B CORRY
金额:
$68.73万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-24 至 2012-07-31
关键词:
3&apos Untranslated RegionsAutoimmune ProcessAutoimmunityB-LymphocytesBindingBioinformaticsCD4 Positive T LymphocytesCXCL10 geneCandidate Disease GeneCause of DeathCellsChronicChronic Obstructive Airway DiseaseCluster AnalysisDataDevelopmentDiagnosisDiseaseDisease OutcomeElastinFoundationsFunctional disorderGene Expression ProfileGene Expression ProfilingGeneticHumanImmunologic MarkersIn VitroIndividualInflammationInflammatoryLaboratoriesLeadLibrariesLungLung InflammationLung diseasesMalignant neoplasm of prostateMatrix MetalloproteinasesMessenger RNAMicroRNAsModificationMolecularObstructionOutcomePatientsPatternPeripheral Blood Mononuclear CellPredictive ValueProteinsPsoriasisPulmonary EmphysemaQuality of lifeRNARNA InterferenceRegulatory PathwayRelative (related person)ResearchRespiratory physiologySmokerSmokingStagingStructure of parenchyma of lungT-LymphocyteTechnologyTestingTh1 CellsTobacco smokeTranscriptTranslationsUp-Regulationabstractingbasechemokineclinically significantinflammatory markerinsightleukemiamRNA Expressionmolecular phenotypeperipheral bloodpiRNAresponsesmoking cessation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The long-term objective of our laboratories is to understand the immunopathologic basis of inflammatory lung diseases. This proposal specifically seeks to understand the significance of microRNA (miRNA) and piwi interacting protein RNA (transposon silencing RNA; piRNA) signatures in smoking-related lung disease marked by chronic obstructruction (chronic obstructive pulmonary disease; COPD) and lung parenchymal loss (emphysema). Tobacco smoke induced COPD/emphysema is now the fourth leading cause of death in the industrialized world and is expected shortly to become the third. Despite smoke cessation, a subset of all smokers ultimately develop COPD/emphysema, suggesting that the chronic inflammation that underlies disease is, to a large degree determined by genetic factors. Because COPD/emphysema is often diagnosed at a late stage, when irreversible lung destruction has resulted in significantly impaired lung function and quality of life, markers of severe lung disease that appear early in the course of COPD/emphysema and which can be used to predict rapid loss of lung function are needed. We have previously demonstrated that emphysema is associated with autoimmune CD4+ T cell and B cell responses directed against the major structural matrix protein of the lung, elastin. Moreover, T helper type 1 (Th1) cell-elicited chemokines, including CXCL10, coordinate the upregulation of matrix metalloproteinases (MMPs) that ultimately lead to elastin destruction and the loss of lung structural integrity. Thus, T cell, but also B cell, specific anti-elastin responses in smokers are potentially valuable indicators of later lung destruction, but it remains unclear if these inflammatory markers develop sufficiently early in asymptomatic smokers to provide clinically useful predictions. MiRNAs are 21nt RNA transcripts that bind to the 3' untranslated region (UTR) of mRNAs to suppress protein translation. Unique expression patterns of the approximately 460 known human miRNAs in diseases as diverse as leukemia, prostate cancer, the chronic inflammatory conditions such as psoriasis, have previously been shown to correlate with clinically significant outcomes. We hypothesize that unique expression patterns of lung miRNAs and closely related piRNAs correlate with inflammatory markers of anti-elastin autoimmunity. Moreover, we postulate that lung miRNA markers of emphysema are recapitulated in peripheral blood of the same individuals and may be used to predict the onset of autoimmune dysfunction. To test these hypotheses, we will establish primary miRNA and piRNA signatures within the human lung and peripheral blood mononuclear cell short transcriptomes that characterize smoking-induced COPD/emphysema; identify miRNA dependent regulatory pathways controlling human smoking-induced COPD/emphysema; and determine the miRNA and piRNA relationships that characterize human Th1 and Th17 cells. (End of Abstract)
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
Inaugural Genomics Automation Congress and the coming deluge of sequencing data.
首届基因组学自动化大会和即将到来的测序数据洪流。
DOI:
10.1586/erm.10.58
发表时间:
2010
期刊:
Expert review of molecular diagnostics
影响因子:
5.1
作者:
[Creighton,ChadJ]
通讯作者:
Creighton,ChadJ
DOI:
10.1016/j.vaccine.2015.11.055
发表时间:
2016-01-20
期刊:
Vaccine
影响因子:
5.5
作者:
[Mbawuike IN, Atmar RL, Patel SM, Corry DB, Winokur PL, Brady RC, Chen WH, Edwards KM, Creech CB, Walter EB Jr, Frey SE, Belshe RB, Goll JB, Hill H, Keitel WA]
通讯作者:
Keitel WA
DOI:
10.1093/nar/gks1098
发表时间:
2013-01
期刊:
Nucleic acids research
影响因子:
14.9
作者:
[Polikepahad S, Corry DB]
通讯作者:
Corry DB
Molecular and Cellular Dissection of miRNAs in Controlling Allergic Airway Inflammation in Mice
-
批准号:10477187
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:DAVID B CORRY
-
依托单位:
Molecular and Cellular Dissection of miRNAs in Controlling Allergic Airway Inflammation in Mice
-
批准号:10664926
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:DAVID B CORRY
-
依托单位:
IMPACC-MEDVAMC
-
批准号:10202368
-
项目类别:
-
资助金额:$16.29万
-
财政年份:2020
-
负责人:DAVID B CORRY
-
依托单位:
Molecular and Cellular Dissection of miRNAs in Controlling Allergic Airway Inflammation in Mice
-
批准号:10012111
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:DAVID B CORRY
-
依托单位:
IMPACC-MEDVAMC
-
批准号:10265764
-
项目类别:
-
资助金额:$32.8万
-
财政年份:2020
-
负责人:DAVID B CORRY
-
依托单位:
MECHANISM AND FUNCTION OF LET-7, A NOVEL MODULATOR OF TH17-DEPENDENT EMPHYSEMA
-
批准号:10240489
-
项目类别:
-
资助金额:$40.15万
-
财政年份:2018
-
负责人:DAVID B CORRY
-
依托单位:
MECHANISM AND FUNCTION OF LET-7, A NOVEL MODULATOR OF TH17-DEPENDENT EMPHYSEMA
-
批准号:10470262
-
项目类别:
-
资助金额:$40.15万
-
财政年份:2018
-
负责人:DAVID B CORRY
-
依托单位:
Pathogenesis of Polymicrobial Cerebritis-Related Dementia
-
批准号:10119639
-
项目类别:
-
资助金额:$32.08万
-
财政年份:2018
-
负责人:DAVID B CORRY
-
依托单位:
FUNGAL PATHOGENESIS OF MODERATE TO SEVERE ASTHMA
-
批准号:10357580
-
项目类别:
-
资助金额:$50.52万
-
财政年份:2018
-
负责人:DAVID B CORRY
-
依托单位:
MECHANISM AND FUNCTION OF LET-7, A NOVEL MODULATOR OF TH17-DEPENDENT EMPHYSEMA
-
批准号:9766362
-
项目类别:
-
资助金额:$40.15万
-
财政年份:2018
-
负责人:DAVID B CORRY
-
依托单位:
MECHANISM AND FUNCTION OF LET-7, A NOVEL MODULATOR OF TH17-DEPENDENT EMPHYSEMA
-
批准号:10001079
-
项目类别:
-
资助金额:$40.15万
-
财政年份:2018
-
负责人:DAVID B CORRY
-
依托单位:
STAT Inhibitors for Asthma Therapy
-
批准号:9202192
-
项目类别:
-
资助金额:$22.75万
-
财政年份:2016
-
负责人:DAVID B CORRY
-
依托单位:
Th1 and Th17 Mediators in Experimental Emphysema
-
批准号:9085352
-
项目类别:
-
资助金额:$39.13万
-
财政年份:2013
-
负责人:DAVID B CORRY
-
依托单位:
Th1 and Th17 Mediators in Experimental Emphysema
-
批准号:8510061
-
项目类别:
-
资助金额:$37.25万
-
财政年份:2013
-
负责人:DAVID B CORRY
-
依托单位:
Th1 and Th17 Mediators in Experimental Emphysema
-
批准号:8701133
-
项目类别:
-
资助金额:$38.34万
-
财政年份:2013
-
负责人:DAVID B CORRY
-
依托单位:
Carbon Black Induced Activation of Lung APCs
-
批准号:8542423
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:DAVID B CORRY
-
依托单位:
Carbon Black Induced Activation of Lung APCs
-
批准号:8670556
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:DAVID B CORRY
-
依托单位:
Molecular Phenotypes for Lung Diseases
-
批准号:7691799
-
项目类别:
-
资助金额:$69.25万
-
财政年份:2008
-
负责人:DAVID B CORRY
-
依托单位:
Molecular Phenotypes for Lung Diseases
-
批准号:7902047
-
项目类别:
-
资助金额:$69.22万
-
财政年份:2008
-
负责人:DAVID B CORRY
-
依托单位:
Environmental Proteinases in Human/Experimental Asthma
-
批准号:7150845
-
项目类别:
-
资助金额:$26.32万
-
财政年份:2006
-
负责人:DAVID B CORRY
-
依托单位:
海外基金